RioTech is a spin-out company which is developing novel therapeutics from intellectual property around Hepatitis C virus infection. The founders are Professor Howard Thomas, Dr Mark Thursz, Dr Peter Karayiannis and Professor Graham Foster (now based at Queen Mary & Westfield College) from Imperial College and Professor Adrian Hill from Oxford University. RioTech was seed funded with £250,000 from the Imperial based University Challenge Seed Fund in 2003.
http://www.sanofi-synthelabous.com
Sanofi is a French multi-national health care corporation dedicated to developing novel and innovative therapeutic agents for a wide range of clinical disorders. Xaliproden is an original Sanofi compound which exhibits neurotrophic and neuroprotective effects. It is being developed primarily as a potential treatment for ALS. Xaliproden is a nonpeptide compound that possesses neurotrophin-like activity. The compound reduces the histological (tissue), neurochemical and functional deficiencies produced in widely divergent models of experimental neurodegeneration. The ability of Xaliproden to increase the innervation of human muscle cells by spinal cord explants and to prolong the survival of mice suffering from progressive motor neuronopathy suggests the compound might be an effective therapy for the treatment of ALS. Even though the mechanism by which Xaliproden produces its neurotrophic and neuroprotective effects is not fully understood, it is thought to be related to the compound's ability to mimic the activity or stimulate the biosynthesis of a number of neurotrophins (such as NGF and BDNF) originating within the body.
Chlorion Pharma, Inc. is a privately-held drug discovery company advancing next-generation CNS therapeutics to the clinic. Currently, Chlorion is focused on the development of small-molecule, disease-modifying compounds for the treatment of neuropathic pain, and subsequently for the treatment of epilepsy, bipolar disease and migraine. Chlorion's head office and research and development laboratories are located in Quebec City, Canada.
PolyMASC Pharmaceuticals plc was incorporated in 1995 to commercialize the intellectual property generated by the scientific team at the Molecular Cell Pathology Laboratory of the Royal Free Hospital School of Medicine, University of London. The company develops and licenses out proprietary formulation technologies, therapeutics and biodiagnostic reagents. PolyMASC has three major technologies: protoMASC , a linkerless and biologically optimised process for polymer modification of proteins and peptides, and lipoMASC for PEGylation of liposomes. PolyMASC's novel ViraMASC technology, launched in July 1998 (the technology licensed to Onyx), is a polymer coating system for viruses which enables gene therapy vehicles to evade circulating antibodies and enhances tumour localisation of viruses after intravenous injection. PolyMASC believes that its platform technologies add value to many classes of pharmaceuticals and in many instances, are enabling.
BioMS Medical Corp. (BioMS) is a biotechnology company engaged in the development and commercialization of therapeutic technologies for the treatment of multiple sclerosis (MS). During the year ended December 31, 2007, BioMS conducted a number of clinical trials with MBP8298: two pivotal Phase III clinical trials (MAESTRO-01 and MAESTRO-03), one open label trial (MAESTRO-02) in secondary progressive MS, and one Phase II trial in relapsing remitting MS (MINDSET-01). During 2007, BioMS is conducted the MAESTRO-01 trial, a pivotal Phase II/III, multi-centre, double blind, placebo-controlled trial designed to evaluate the safety and efficacy of MBP8298 in patients with secondary progressive MS. In January 2007, approval was received from the United States Food and Drug Administration for the initiation of the MAESTRO-03 trial, a pivotal Phase III clinical trial in the United States to investigate the use of MBP8298 as a treatment for patients with secondary progressive MS. (Source: ARS)
Progen Pharmaceuticals Limited, formerly Progen Industries Limited, is an Australia-based biotechnology company engaged in the discovery, development and commercialization of small molecule pharmaceuticals for the treatment of cancer. The Company’s pipeline product candidate, PI-88, is a multi-targeted cancer therapeutic, which is in development for the treatment of post-resection liver cancer, metastatic melanoma, non-small cell lung cancer (NSCLC), multiple myeloma and hormone refractory prostate cancer. The indication for PI-88 is for the treatment of post-resection liver cancer and is in the late stages of Phase II clinical development. In addition to PI-88, the Company is actively engaged in other drug development efforts. Its second product candidate, PI-166, is a targeted cytotoxic drug in a Phase Ib clinical trial for the treatment of inoperable liver cancer. PI-166 is a formulation with a high affinity for primary liver cancer cells. (Source: ARS)
ChemGenex Pharmaceuticals Limited (ChemGenex) is an integrated biopharmaceutical development company with expertise in the discovery and the development of oncology drugs. As of June 30, 2008, ChemGenex had two small molecule drug candidates in human clinical trials (Omacetaxine, formerly called Ceflatonin in phase II/III and Quinamed in phase II) and a pipeline of development-stage compounds and targets, including CXS299 and CXS2101. ChemGenex focuses to develop targeted medicines for the treatment of cancer by identifying and targeting the genetic components of a range of cancer types. Autogen Research Pty Ltd was demerged on December 13, 2007. The company has two molecules in clinical trials and has a supporting suite of pre-clinical anti-cancer compounds in development. In June 2008, the Company announced that it had acquired commercialization rights for Omacetaxine from its development partner Stragen Pharma. (Source: ARS)
At ILEX, we continue to research and acquire compounds with unique mechanisms of action, targeting novel receptors. We are focused on building a portfolio of oncology compounds that are different than those already available to patients and that provide new hope with effective and safe treatments for cancer. The ILEX history of drug development remains the core competency of the company and is now focused on ILEX's own pipeline. In addition to its strong scientific and clinical staff, ILEX has a knowledgeable management team with extensive pharmaceutical industry experience. ILEX is building a product-driven biopharmaceutical company focused primarily in oncology. ILEX has a marketed product, CAMPATH® (alemtuzumab) in the United States and MABCAMPATH® in the European Union, and is advancing an innovative and diversified pipeline of compounds.
DOR Biopharma, Inc. (DOR) is a research and development biopharmaceutical company focused on the development of oral therapeutic products intended for areas of unmet medical need, as well as therapeutic and vaccine products. The Company operates in two business segments: BioDefense and BioTherapeutics. Its BioDefense business segment consists of converting biodefense vaccine programs from early stage development to advanced development and manufacturing. DOR's BioTherapeutic business segment consists of development of oral beclomethasone dipropionate (orBec) and other BioTherapeutics products, such as Oraprine, lipid polymer micelle (LPM), LPE and PLP Systems for Delivery of Water-Insoluble Drugs.
Isotechnika Inc. (Isotechnika) is an international biopharmaceutical company. The Company’s primary business is the development of immunosuppressive drugs. In addition, the Company operates a diagnostic business segment. The diagnostic segment is operated through its wholly owned subsidiary, Isodiagnostika Inc. (operating as Isotechnika Diagnostics). The Company has developed and sells a non-invasive, non-radioactive diagnostic breath test kit called Helikit. This test incorporates the Company’s manufacturing process and 13C urea formulation to detect the Helicobacter pylori (H. pylori) bacterium. Isotechnika’s lead drug, ISA247, is a next generation calcineurin inhibitor. ISA247 is being investigated for the prevention of kidney rejection following transplantation, the treatment of psoriasis (an autoimmune disease), and for ophthalmic diseases, such as uveitis. The Company’s other wholly owned subsidiary is Isotechnika International Inc. (Source: ARS)
SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities.
LAB International is an integrated drug development company focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies. LAB's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "LAB", on the Frankfurt Regulated Unofficial Market under the symbol "LD9.F" and on XETRA under the symbol "LD9.DE" with 74.5 million shares outstanding.
Adherex Technologies Inc. a biopharmaceutical company focused on cancer therapeutics with preclinical and clinical product candidates. The Company has three product candidates in the clinical stage of development. Eniluracil is a dihydropyrimidine dehydrogenase (DPD) inhibitor that was previously under development by GSK for the treatment of cancer. Adherex Technologies is developing eniluracil to enhance the therapeutic value and effectiveness of 5-fluorouracil (5-FU), an oncology agent. ADH-1 is an anti-cancer drug that selectively targets N-cadherin present on certain tumor cells and the established blood vessels that supply tumors. STS is a chemoprotectant that has been shown in Phase I and Phase II clinical studies conducted by investigators at Oregon Health & Science University (OHSU) to reduce the disabling loss of hearing in both adults and children treated with platinum-based anti-cancer agents. (Source: 10-K)
UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.6 billion euro in 2007. UCB S.A. is listed on the Euronext Brussels (Euronext: UCB). Schwarz Pharma is a member of UCB-Group.
ImClone Systems Incorporated (ImClone) is a biopharmaceutical company that develops a portfolio of targeted biologic treatments designed to address the medical needs of patients with cancer. The Company focuses on two systems for treating cancer: growth factor blockers and angiogenesis inhibitors. Its commercially available product, ERBITUX (cetuximab), is an antibody approved by the United States Food and Drug Administration (FDA). On March 1, 2006, the FDA approved ERBITUX for use in combination with radiation therapy for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and as a single agent in recurrent or metastatic SCCHN. In addition to developing and commercializing ERBITUX, the Company has also advanced a number of investigational agents to various stages of clinical development, including those targeting angiogenesis and growth signaling mechanisms, which can be used to treat various kinds of cancer and other diseases.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory